BioCentury on BioBusiness,
Tools & Techniques
Tangled in the 3-drug web
Monday, October 11, 1999
While new therapies for AIDS are clearly needed due to viral resistance and reservoirs of infectious HIV, the widespread use of triple combination therapy presents a clinical challenge to compounds in development, if only for the number of possible permutations and combinations of drugs. However, this also means that the failure of one combination in pivotal trials does not sound the death knell of a new compound.
Thus the failure of Triangle Pharmaceuticals Inc.'s Coactinon emivirine non-nucleoside reverse transcriptase inhibitor (NNRTI) in a triple combination regimen including a protease inhibitor (PI) is not the end of the world for the company. Instead, VIRS believes that Coactinon may be best used as initial HIV therapy in regimens that do not contain a PI.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]